Policy & Advocacy Updates This quarter marked an exciting period of growth and progress for MAPS’ Policy & Advocacy team. Through strategic partnerships, innovative research, coalition building, …
Washington, D.C., July 7, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS) released an Ibogaine Investigator’s Brochure (IB), a comprehensive scientific and regulatory resource …
Washington, D.C., June 2, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS) today announced its Psychedelics for System-Impacted People (PSIP) project, a research, education, and …
Denver, Colorado; May 13, 2026 —The Multidisciplinary Association for Psychedelic Studies (MAPS) announced that early bird registrations are now open for Psychedelic Science 2027 (PS27), taking place …
DENVER, May 5, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced a partnership with the Colorado Department of Revenue’s Natural Medicine Division to provide MAPS’ …
As psychedelics enter the mainstream, new questions arise about how care models can serve diverse populations. To date, research has largely focused on veterans, first responders, and survivors of sexualized …
2026 is an important year for psychedelic state policy reform, reflecting the emerging evidence, creative leadership, and increasing confidence of a more mature movement. As the public deepens its understanding …
ICEERS’ psychedelic research study, Keeping the Candles Burning: Empowering Peacemakers in Dark Times, was supported through a MAPS grant as part of our ongoing commitment to advancing multidisciplinary …
Using funding provided by the Ohio Department of Behavioral Health, the Center for Psychedelic Drug Research and Education (CPDRE) will equip more than 127,000 Ohio professionals with skills in psychedelic …
Richard Lee, a pioneering activist who dedicated his life to ending the war on cannabis and to creating opportunities for dignity, education, and freedom, passed away on July 27 in Houston, Texas, from …
There is no excerpt because this is a protected post.
On August 23, 2024, MAPS submitted a Formal Dispute Resolution Request to appeal the Clinical Hold placed on the Phase 2 study of cannabis for Veterans with PTSD (MJP2) by the FDA Division of Psychiatry …